Table 5.
Results of sensitivity analyses.
| Sulfonylureas | Metformin | HR (95% CI) | |||
|---|---|---|---|---|---|
| Cases/Person-years | Incidence (/100,000 person years) | Cases/Person-years | Incidence (/100,000 person years) | ||
| Alternative models | |||||
| Subdistribution hazard function | 462/54514 | 847 | 291/40082 | 726 | 1.10 (0.94–1.28) |
| MSM with raw weights | 462/54514 | 847 | 291/40082 | 726 | 1.09 (0.93–1.27) |
| Parametric g-formula | 462/54514 | 847 | 291/40082 | 726 | 1.06 (0.89–1.27) |
| Latency periods (months), follow-up from the index date | |||||
| 0 months | 570/55437 | 1028 | 393/41064 | 957 | 1.04 (0.90–1.19) |
| 12 months | 383/51312 | 746 | 233/36962 | 630 | 1.11 (0.94–1.33) |
| 18 months | 311/47912 | 649 | 190/33535 | 567 | 1.08 (0.89–1.31) |
| 24 months | 262/44242 | 592 | 160/30055 | 532 | 1.07 (0.86–1.32) |
| Latency periods (months), follow-up after the latency periods | |||||
| 6 months | 455/45063 | 1010 | 278/31759 | 875 | 1.10 (0.94–1.28) |
| 12 months | 319/31780 | 1004 | 197/21234 | 928 | 1.11 (0.94–1.32) |
| 18 months | 303/29888 | 1014 | 172/19388 | 887 | 1.06 (0.87–1.28) |
| 24 months | 255/24342 | 1048 | 143/15257 | 937 | 1.05 (0.85–1.29) |
| Excluding individuals missing FBG or HbA1c at baseline | 392/46678 | 840 | 265/33946 | 781 | 1.03 (0.87–1.21) |
| Alternative analysis strategies | |||||
| Intention-to-treat | 908/115086 | 789 | 573/86985 | 659 | 1.07 (0.97–1.19) |
| Per-protocol | 404/50206 | 805 | 233/37181 | 627 | 1.08 (0.91–1.27) |
| Hospitalization within one year of cancer diagnosis | 410/54514 | 752 | 240/40082 | 599 | 1.15 (0.97–1.36) |